IL111682A0 - Recombinant viruses and their use in gene therapy - Google Patents

Recombinant viruses and their use in gene therapy

Info

Publication number
IL111682A0
IL111682A0 IL11168294A IL11168294A IL111682A0 IL 111682 A0 IL111682 A0 IL 111682A0 IL 11168294 A IL11168294 A IL 11168294A IL 11168294 A IL11168294 A IL 11168294A IL 111682 A0 IL111682 A0 IL 111682A0
Authority
IL
Israel
Prior art keywords
gene therapy
recombinant viruses
viruses
recombinant
therapy
Prior art date
Application number
IL11168294A
Other languages
English (en)
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL111682A0 publication Critical patent/IL111682A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11168294A 1993-11-18 1994-11-17 Recombinant viruses and their use in gene therapy IL111682A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9313766A FR2712602B1 (fr) 1993-11-18 1993-11-18 Virus recombinants, préparation et utilisation en thérapie génique.

Publications (1)

Publication Number Publication Date
IL111682A0 true IL111682A0 (en) 1995-01-24

Family

ID=9452970

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11168294A IL111682A0 (en) 1993-11-18 1994-11-17 Recombinant viruses and their use in gene therapy

Country Status (12)

Country Link
US (2) US5837531A (xx)
EP (1) EP0729516A1 (xx)
JP (1) JPH09504955A (xx)
KR (1) KR100368292B1 (xx)
AU (1) AU699867B2 (xx)
CA (1) CA2176585A1 (xx)
FI (1) FI962114A (xx)
FR (1) FR2712602B1 (xx)
IL (1) IL111682A0 (xx)
NO (1) NO317725B1 (xx)
WO (1) WO1995014101A1 (xx)
ZA (1) ZA949103B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5877010A (en) * 1994-05-02 1999-03-02 University Of Washington Thymidine kinase mutants
EP0707071B1 (en) 1994-08-16 2003-07-30 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
DE19608751B4 (de) 1996-03-06 2006-05-18 Medigene Ag Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
ATE344322T1 (de) 1998-02-13 2006-11-15 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
CN1405312A (zh) * 2001-01-18 2003-03-26 中山卫健生物科技有限公司 一种能特异性杀灭eb病毒相关肿瘤的重组病毒及其构建方法
WO2003047634A2 (en) * 2001-12-06 2003-06-12 University Health Network Nucleic acids and methods for treating ebv-positive cancers
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
WO2004038008A2 (en) * 2002-10-25 2004-05-06 University Of Massachusetts Modulation of cellular proliferation
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA027346B1 (ru) 2008-06-17 2017-07-31 Милленниум Фармасьютикалз, Инк. Соединения боронатного эфира и его фармацевтические составы
NZ725948A (en) 2014-05-20 2024-01-26 Takeda Pharmaceuticals Co Boron-containing proteasome inhibitors for use after primary cancer therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939088A (en) * 1987-02-18 1990-07-03 Meloy Laboratories Inc. Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5194601A (en) * 1989-09-18 1993-03-16 Wisconsin Alumni Research Foundation Lytic origin of replication for Epstein-Barr virus (EBV)
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
CA2091346C (en) * 1990-09-14 2007-04-24 Philip Frost Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
NO961977D0 (no) 1996-05-14
WO1995014101A1 (fr) 1995-05-26
FR2712602B1 (fr) 1996-02-09
NO317725B1 (no) 2004-12-13
FR2712602A1 (fr) 1995-05-24
KR100368292B1 (ko) 2003-12-24
AU699867B2 (en) 1998-12-17
US5837531A (en) 1998-11-17
FI962114A0 (fi) 1996-05-17
AU8147194A (en) 1995-06-06
JPH09504955A (ja) 1997-05-20
USRE39078E1 (en) 2006-04-25
NO961977L (no) 1996-05-14
FI962114A (fi) 1996-05-17
CA2176585A1 (fr) 1995-05-26
ZA949103B (en) 1995-07-21
EP0729516A1 (fr) 1996-09-04

Similar Documents

Publication Publication Date Title
IL111681A0 (en) Recombinant viruses and their use in gene therapy
IL115584A0 (en) Viral vectors and their use in gene therapy
ZA945012B (en) Viral vectors and their use in gene therapy
ZA951803B (en) Recombinant viruses their preparation and their therapeutic use
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
IL111682A0 (en) Recombinant viruses and their use in gene therapy
AU4032893A (en) Human papilloma virus genes and their use in gene therapy
SG54275A1 (en) Dna coding for decarbamylase improved in thermostability and use thereof
GB9214857D0 (en) Human nucleic acid fragments and their use
EP0623020A4 (en) PYROPHEOPHORBIDES AND THEIR USE IN PHOTODYNAMIC THERAPY.
GB9414925D0 (en) Electrode and preparation thereof
EP0752472A4 (en) NEW GENE FROM CORYNEBACTERIUM AND ITS USE
IL114982A0 (en) Use of a defective recombinant adenovirus in gene therapy
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
ZA952242B (en) Recombinant viruses their preparation and their use in gene therapy
AU7665396A (en) Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
ZA952244B (en) Recombinant viruses their preparation and their use in gene therapy
FR2725213B1 (fr) Vecteurs viraux et utilisation en therapie genique
GB2279956B (en) Recombinant human and rat AMP-protein kinases
ZA952286B (en) Recombinant viruses their preparation and their use in gene therapy
EP0692537A3 (en) Recombinant gibberellin DNA and its use
ZA952243B (en) Recombinant viruses their preparation and their use in gene therapy
EP0690917A4 (en) EPSTEIN-BARR VIRUS PROTEIN OBTAINED BY RECOMBINATION AND ITS USE AS A VACCINE
GB9501907D0 (en) Allatostatins and their use
GB9405875D0 (en) Recombinant molecules and their use in gene transfer